SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
CAR-T
J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data
With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off competition from emerging CAR T therapies such as Gilead and Arcellx’s anito-cel.
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech obtained the candidate when it bought Biotheus last month in an acquisition deal that could reach up to $950 million.
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Podcast
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment model; Eli Lilly and Novo Nordisk pump new funds into manufacturing; and AbbVie makes a Cerevel comeback while uniQure clears a path toward accelerated approval in Huntington’s disease.
December 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Group Of Employees Being Fired By Their Company.
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to developing therapies for fibrosis, oncology and autoimmune diseases.
December 10, 2024
 · 
2 min read
 · 
Angela Gabriel
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified Huntington’s Disease Rating Scale, and neurofilament light chain levels to support the accelerated approval of its gene therapy AMT-130.
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
GSK's headquarters office building in Poznan, Poland
Cancer
GSK Touts 42% Survival Benefit for Blenrep in Multiple Myeloma, Strengthening Bid for Market Return
The overall survival edge over J&J’s Darzalex will help GSK strengthen its case as it plots the market comeback of Blenrep, which was pulled after a failed confirmatory study.
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
A player checkmates the king, target in the background, chess game and strategy concept, vintage style poster
CAR-T
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: An Eli Lilly Research Laboratories sign/
Cancer
Lilly’s Strong Phase III Survival Data for Jaypirca Clouded by Deaths
According to Jake Van Naarden, president of Lilly Oncology, the excess deaths could be due to the high rate of crossover in BRUIN CLL-321.
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
Relmada Therapeutics will halt two Phase III trials of a major depressive disorder drug after a futility assessment and explore strategic alternatives including a potential sale to maximize shareholder value.
December 9, 2024
 · 
1 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS